Amitiza (lubiprostone) is a medication prescribed to treat chronic idiopathic constipation, irritable bowel syndrome with constipation (IBS-C), and opioid-induced constipation in adults [1]. It works by increasing fluid secretion into the intestines, which softens stool and stimulates bowel movements [1].
How does Amitiza work to relieve constipation?
Amitiza contains the active ingredient lubiprostone, a bicyclic fatty acid that acts as a prostaglandin E1 (PGE1) derivative. Lubiprostone selectively activates specifically chloride channels (ClC-2) on the apical membrane of intestinal epithelial cells [1]. This activation leads to increased secretion of chloride-rich fluid into the intestinal lumen. This fluid softens the stool and increases intestinal motility, facilitating bowel movements [1].
What are the approved uses for Amitiza?
Amitiza is approved for the treatment of the following conditions in adults:
* Chronic idiopathic constipation (CIC): This refers to constipation that has lasted for at least 12 weeks and has no identifiable cause [1].
* Irritable bowel syndrome with constipation (IBS-C): This is a functional gastrointestinal disorder characterized by abdominal pain and altered bowel habits, specifically constipation [1].
* Opioid-induced constipation (OIC): This type of constipation is a common side effect of taking opioid pain medications [1].
What side effects can Amitiza cause?
Common side effects of Amitiza include nausea, diarrhea, abdominal pain, flatulence, and headache [1]. Nausea is the most frequently reported side effect and may be reduced by taking the medication with food [1]. Patients should report any severe or persistent side effects to their healthcare provider [1].
When does Amitiza's patent protection expire?
The patent protection for Amitiza is complex and has been subject to various challenges and extensions. According to DrugPatentWatch.com, the key patents associated with lubiprostone have expiration dates that vary, with some significant protections having already expired and others potentially extending into the future depending on legal challenges and exclusivities [2]. For detailed and up-to-date information on specific patent expiries, consulting resources like DrugPatentWatch.com is recommended [2].
Are there alternative treatments for constipation?
Yes, several alternative treatments are available for constipation, depending on the cause and severity. These include lifestyle modifications such as increasing dietary fiber and fluid intake, and regular exercise. Over-the-counter medications like bulk-forming laxatives (e.g., psyllium), osmotic laxatives (e.g., polyethylene glycol), and stimulant laxatives (e.g., senna, bisacodyl) are also commonly used [3]. Prescription medications, including other secretagogues or motility agents, may be prescribed by a doctor in certain cases [3].
What is the typical dosage and administration of Amitiza?
The recommended dosage of Amitiza varies depending on the condition being treated. For chronic idiopathic constipation and IBS-C, the typical dose is 24 micrograms (mcg) taken orally twice daily [1]. For opioid-induced constipation, the dose is also 24 mcg orally twice daily [1]. It is generally recommended to take Amitiza with food to help minimize nausea [1].
Who manufactures Amitiza?
Amitiza was originally developed by Sucampo Pharmaceuticals and is currently marketed by Takeda Pharmaceuticals [4].
What is the clinical data supporting Amitiza's efficacy?
Clinical trials have demonstrated that Amitiza is effective in improving bowel movement frequency and consistency in patients with chronic idiopathic constipation and IBS-C [1]. Studies have shown significant increases in the number of spontaneous bowel movements compared to placebo [1]. For OIC, clinical data indicates Amitiza can restore bowel function in patients who are on chronic opioid therapy [1].
Can generic versions of Amitiza be made available?
The availability of generic versions of Amitiza depends on the expiration of its patents and any associated market exclusivities. As patent protections expire, generic manufacturers may seek to produce and market their own versions of lubiprostone, potentially leading to lower costs [2].
---
Sources:
[1] https://www.amitiza.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.mayoclinic.org/diseases-conditions/constipation/diagnosis-treatment/drc-20354261
[4] https://www.takeda.com/